And the big advantage we have is that if we take the route thru China, there is likely to be a faster approval route than anyone going first thru Europe or the US. So we may be able to get massive amounts of data in China that would then be a strong case for quick approval in the West, as well as putting us on the A-list for contacts when the next new virus comes around.
(3)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links